Every year candidal infections affect a great number of the population, and annually the number of patients is
M odern pharmacy and medicine require creation of a vaccine against candidiasis. This disease constantly affects a great number of the population, and every year the number of patients is growing. The incidence rate of candidiases is associated with irrational use of medicines affecting the immunity and distribution of concomitant diseases suppressing the immune system [1] . The market potential of therapeutic vaccines for treating candidiasis is constantly growing [3, 7] . So, for example, a vaccine against recurrent candidiasis is specified as the vaccine that improves the quality of life [3, 5] . And vulvovaginal candidiasis, of course, is not the disease that is life threatening, but can have a devastating impact on the quality of life of many women in the world [5] . A vaccine for treating candidiasis should primarily be designed as a tool for prevention or therapy of candidal infections in patients with a weakened immune system since they have extremely high morbidity and mortality [1] .
To fight candidal infections the studies are carried out actively in recent years both on the territory of the former Soviet Union, and in Europe and America [3] [4] [5] [6] [7] [8] . At present there are some variants of various vaccines being tested in preclinical and clinical trials in the USA [3] . It should be noted that currently no domestic vaccine is produced in Ukraine and no imported vaccines for prevention and treatment of candidiases have been registered. Therefore, development of a vaccine against candidal infection is the topical issue of modern medicine and pharmacy.
At the premises of the National University of Pharmacy at the Biotechnology Department and the Department of Microbiology, Virology and Immunology the authors have developed the method of cell disintegration of Candida albicans fungi using the ultrasonic cell disrupter at the wavelength of 22 kHz and exposure of 15 min. The use of subunits of cells is a promising direction in developing vaccines [2] . The solution of fungal cell disintegration obtained was filtered through a "Vladipore" membrane MFА-МА No.3 providing separation of the biological material with the size of 10 kDa and its concentration. Then prefiltration using filters with the pore diameter of 0.45 µm and sterilizing filtration using filters with the pore diameter of 0.22 µm were carried out. Proteins and polysaccharides possessing the antigenic properties are in the composition of the cell extract of Candida fungi. According to the requirements of the SPhU determination of the active substance in such case is conducted by protein. In our previous research the efficiency of the cell-associated antigens of C. albicans fungi with the protein concentration of 3 mg/ml in preventing candidal infection was determined.
The aim of this work is the immunobiological assessment of the cell-associated antigens of Candida albicans fungi in treating candidiases. 
Materials and Methods
The immunological action of the cell-associated antigens of C. albicans fungi in treating candidiases was determined in the experiments with healthy two month white mice weighing 18-22 g. There were six animals in the control and experimental groups each; they were kept in the same conditions on a standard diet. Before the research the animals acclimatized themselves under experimental room conditions. The mice were preliminary infected with the candidal infection. For this purpose the suspension of C. albicans fungi in the amount of 20 mln of cells in the volume of 1 ml was used; the fungi were introduced with an interval of 1 hour. After that the symptoms of the disease indicating development of candidiasis in animals were revealed. These main symptoms were unkempt appearance, refusal to eat, the body weight loss, dysfunctions of the excretory organs, etc. In 5 days after infection the cell-associated antigens of C. albicans fungi under research with the protein concentration of 3 mg/ml in the volume of 0.2 ml were injected intramuscularly to mice in the upper part of the rear right paw. In 14 days the antigens of C. albicans fungi with the protein concentration of 3 mg/ml in the volume of 0.2 ml were injected again in the upper part of the left rear paw. Nothing was given to the animals of the control group. In 14 days the protective functions of the animals' body were determined by the titres of the specific antibodies of C. albicans using enzyme-linked immunoassay (ELISA) according to SphU, ed. І, art. 2.7.1, p. 55-57. For this purpose the reagent kit for immunoassay detection of antibodies of class G was used for C. albicans by means of "Vector-Best" ELISA test system produced in Russia.
Results and Discussion
The results of the research demonstrated that prior the injection the antibody titres of healthy animals were in the range of 1:200 -1:500. It can be explained by a possible contact with the fungus of the Candida genus in the process of life activities of mice or a possible carrier state of this type of fungi since they are part of the normal microflora of animals. After double infection of the cell-associated antigens of C. albicans fungi with the protein concentration of 3 mg/ml with an interval of 14 days there is an increase in the antibody titre within the range of 1:600 -1:4000. The antibody titre in the control group was in the range of 1:400 -1:1000. To obtain reliable results of the study all the values obtained were statistically processed, the median for all groups and its confidence interval were calculated. The median and the confidence interval of the antibody titre in animals of the control and experimental groups before infection was 1:350 ± 98 and 1:400 ± 103; after infection and injections it was 1:2800 ± 795 in animals of the experimental group and 1:800 ± 182 in animals of the control group. Comparing the results obtained in the experimental and control group it is a fair assumption to say that introduction of the cell-associated antigens of Candida albicans stimulates formation of antibodies, which are responsible for the humoral immunity.
In biomedical research there are occasions when comparing individual parameters it is necessary to estimate the significance of the difference between them. A significant difference between the individual indicators of the sampling study suggests the possibility of transferring these findings to the main entity. The confidence factor (Student t-test) is the criterion for assessing the significance of the difference. As a result of the research conducted the confidence coefficients t=3 and t=4 corresponding to t>2 (corresponds to the probability of accurate prediction of 95%) were obtained for the experimental and control groups of animals before and after injection. The research results are given in Table. Based on these data it can therefore be said that the antigens of C. albicans fungi can be potential antigens for development of a vaccine for prevention and treatment of candidal infection. CONCLUSIONS 1. The cell-associated antigens of Candida albicans with the protein concentration of 3 mg/ml in treating candidal infection have been researched. Note: experiment -the cell-associated antigens of C. albicans fungi with the protein concentration of 3 mg/ml, control -intact animals.
2. As a result of the research conducted it has been found that the cell-associated antigens of C. albicans fungi provide high titres of antibodies in all animals in double intramuscular introduction in the volume of 0.2 ml.
3. The antigens of C. albicans fungi with the protein concentration of 3 mg/ml have been selected for further research; based on them it is planned to develop a vaccine for prevention and treatment of candidal infection.
